Hanna Lavén

Hanna Lavén

Auto-generated profile, based on publicly available information

Hanna Lavén

Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EIEmma Inganäs
Emma Inganäs
HLHanna Lavén
Hanna Lavén
RCRémi Caraballo
Rémi Caraballo
FKFredrik Klingegård
Fredrik Klingegård
MEMyLan Eklund
MyLan Eklund
PMPär Matsson
Pär Matsson
Proteolysis targeting chimeras (PROTACs) offer vast new therapeutic opportunities, but their physicochemical properties are difficult to combine with optimal cell permeability and exposure at the target sites. We have systematically analyzed a data set of more than 3500 PROTACs to investigate how the choice of ubiquitin E3 ligands, linker design, and global molecular properties can be optimized to achieve the desired cell membrane interactions and ultimately membrane permeability and intracellular exposure. We find that conformational flexibility leads to environment-dependent shielding of polar functions and improved interactions with cell membranes but that at the same time, extended, linear conformations within the membrane are beneficial. Linker composition was a major factor in determining the folding propensity. Collectively, our results suggest that strategies to rationally design linkers and to shield polarity selectively within the protein-of-interest (POI) ligand and/or E3 ligand domains rather than more extensive folding may be beneficial in the design of permeable and effective PROTACs.